As the kinase activity of CDK12 was required for the proliferation of AML cells with NUP98 fusion oncoproteins, we used the CDK12/13 inhibitor THZ53158 to pharmacologically target CDK12. This evidence concerns the gene CDK12 and acute myeloid leukemia.